open surgery News
-
RevBio Receives a $2 Million NIH Grant to Pursue the Treatment of Wrist Fractures with Its Innovative Bone Adhesive Technology
RevBio, Inc., announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant expected to total $2 million over two years from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of wrist fractures with its patented bone adhesive technology known as Tetranite®. Because the bone ...
By RevBio Inc.
-
Amsel Medical Corporation Announces First-In-Man Clinical Use of the Amsel Occluder Device at NYU Langone Medical Center
Amsel Medical Corporation Announces Industry Exhibit of the Amsel Occluder Device at the 2017 Veith Symposium (NY) November 14-18, 2017. The Amsel Occluder Device is intended for use in open general surgery procedures on tubular structures or vessels wherever a metal ligating clip is indicated and within the size range of 2.0mm to 7.0mm diameter. Amsel Medical Corporation today ...
-
Endospan elects Jeff Elkins as a director
Endospan, a pioneer in off-the-shelf endovascular repair of Aortic Arch Disease including aneurysms and dissections, today announced that it has elected Jeff Elkins to its board of directors. Elkins has been President and CEO of Veniti Inc. since July 2015. Previously, Elkins was COO and earlier CEO of Aptus Endosystems, acquired by Medtronic; and, founding COO of FlowMedica, acquired by ...
-
Versius introduced in leading public hospitals in Egypt
CMR Surgical – the global surgical robotics business – has today announced the launch of its Versius® Surgical Robotic System in Egypt. Versius has been introduced at both Ain Shams University Specialized Hospital and the International Hospital for Urology & Nephrology (IHUN), as CMR works with ATG group to meet significant demand for Versius from one of the largest countries ...
-
FDA Grants NEXUS Aortic Arch Stent Graft System Breakthrough Designation
Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease was recently granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the NEXUS™ Aortic Arch Stent Graft System. The FDA’s Breakthrough Device Designation Program is intended to provide timely access to medical devices that have the potential to provide a more effective ...
-
Endospan Enters Into Strategic Distribution Agreement With CryoLife
Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease, today announced it has entered into strategic distribution and credit facility agreements with CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease. Under the terms of the agreement, CryoLife will have exclusive European distribution rights to NEXUS™, the first ...
-
HipXpert Now Supports DePuy Synthes’ PINNACLE
Surgical Planning Associates, Inc. announces a new HipXpert software release that now includes the addition of DePuy Synthes’ PINNACLE® Acetabular Cup System and the ACTIS®, CORAIL®, SUMMIT®, and TRI-LOCK® Hip Systems to our patient-specific surgery planning and navigation system. HipXpert’s open-platform, 3D surgery planning software now supports more than 20 ...
By HipXpert
-
Kohl`s Cares(R) scholarship program accepting nominations February 1 - March 15, ten national winners to receive $10,000 each
The Kohl's Department Stores (NYSE: KSS) Kohl's Cares Scholarship Program will award more than $415,000 in scholarships and prizes, ranging from $50 Kohl’s gift cards to $10,000 scholarships, honoring young volunteers who have made a positive impact on their communities. Nominations for kids ages six to 18 will be accepted Feb. 1 - March 15 at kohlskids.com. Kohl's enters the 11th year of ...
-
Endospan receives CE mark for HORIZON EVAR system based on robust clinical and pivotal data to treat Abdominal Aortic Aneurysm (AAA)
Endospan, a pioneer in off-the-shelf EndoVascular Aortic Repair (EVAR), announced today that it has received CE marking for its HORIZON Stent Graft System to treat Abdominal Aortic Aneurysm (AAA). “HORIZON is a unique platform that can be used in a 14Fr single-sided approach, generally shortening and simplifying EVAR procedures,” said Kevin Mayberry, CEO. “HORIZON is supported ...
-
1st Successful Heart Tumor Removal Without Open Heart Surgery
EchoPixel has once again contributed to a pioneering procedure at CentraCare – St. Cloud Hospital with the first team to remove a heart tumor without invasive open heart surgery using the novel AlphaVac catheter. Previously CentraCare had been the first to use EchoPixel’s 4D hologram technology to conduct the WATCHMAN implant, which is a one-time, minimally invasive procedure ...
-
Versius surgical robot used for first time in an Italian public hospital
CMR Surgical (CMR) – a global surgical robotics business – today announced the introduction of the Versius® Surgical Robotic System, at Policlinico di Milano, a leading research hospital and care institute (IRCCS), and one of the largest healthcare facilities in Lombardy, Italy. Within the hospital, Versius will be used in a multi-specialty robotics programme including thoracic ...
-
Team Gleason Partners with Synchron to Redefine Accessibility
Team Gleason and Synchron, an endovascular brain computer interface company, today announced a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities like ALS, muscular dystrophy, and cerebral palsy. The partnership will enable Synchron to collaborate with Team Gleason’s expert committees and an ...
-
Lumendi Introduces EZ Glide Hydrophilic Coating for Its DiLumen Endoluminal Interventional Platform (EIP)
Connecticut-based medical device innovator Lumendi, LLC (www.lumendi.com) has launched EZ Glide, a proprietary hydrophilic coating applied to the inner sheath of its DiLumen EIP, a double-balloon endoluminal device that aims to safely improve the navigation of the endoscope through the bowel, create a stabilizing therapeutic zone inside the colon during endoluminal interventions, ...
By Lumendi Ltd.
-
BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial
BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has joined the European REVIVE-HF clinical trial of the Revivent TC™ Transcatheter Ventricular Enhancement System as co-principal investigator. Dr. von Bardeleben heads ...
-
Synchron Announces Long-Term Safety Results from Fully Implanted Endovascular Brain-Computer Interface Stentrode for Severe Paralysis
Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks No Serious Adverse Events Reported after 12 Months Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ device, a small mesh-like material inserted ...
-
JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial
JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinical trial for the Trilogy™ Heart Valve System for severe symptomatic, high-surgical risk aortic regurgitation. Aortic regurgitation (AR) is a condition ...
-
SKI Vascular Center is First Ambulatory Surgical Center in the Nation to Utilize FDA-Approved Ellipsys System for Non-Surgical Dialysis Fistula Creation
Tempe-based interventional nephrologists Randy Cooper, MD and Umar Waheed, MD, and their team at SKI Vascular Center, this week became the first ambulatory surgical center in the US to create a percutaneous arteriovenous fistula (AVF), using the Ellipsys® Vascular Access System, a game-changing innovation for patients with End-Stage Renal Disease (ESRD). The recently FDA-approved Ellipsys ...
-
Medtronic to Acquire Avenu Medical
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the planned acquisition of Avenu Medical, a privately held medical device company based in San Juan Capistrano, Calif. focused on the endovascular (minimally invasive) creation of arteriovenous (AV) fistulae for patients with end-stage renal disease (ESRD) undergoing dialysis. Terms of the transaction were not ...
-
JenaValve Announces Strategic Investment and Licensing Agreement with Peijia Medical Limited
JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced a strategic investment and exclusive technology licensing agreement with Peijia Medical Limited (HKEX: 9996) in China. Under the terms of the agreement, Peijia has made a cash and equity investment in ...
-
JenaValve Announces First European Commercial Implants with the Trilogy™ Heart Valve System
JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. The procedures, which included treatment of both aortic regurgitation1 (AR) and aortic stenosis1 (AS), took place in multiple centers in Germany, marks the official start of the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you